News
AKTS
18.06
+1.46%
0.26
Assessing Aktis Oncology (AKTS) Valuation After Recent Share Price Weakness And Negative Price To Book Ratio
Simply Wall St · 2d ago
Weekly Report: what happened at AKTS last week (0202-0206)?
Weekly Report · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Allurion, Rithm Capital, Medtronic
Reuters · 02/03 18:47
BUZZ-J.P. Morgan initiates coverage of Aktis Oncology with 'overweight' rating
Reuters · 02/03 16:01
AKTIS ONCOLOGY INC <AKTS.O>: BOFA GLOBAL RESEARCH INITIATES COVERAGE WITH BUY RATING; PRICE OBJECTIVE $34
Reuters · 02/03 14:56
Adobe downgraded, Palantir upgraded: Wall Street’s top analyst calls
TipRanks · 02/03 14:35
This GCI Liberty Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday
Benzinga · 02/03 14:10
Aktis Oncology Price Target Announced at $31.00/Share by Leerink Partners
Dow Jones · 02/03 12:39
Aktis Oncology Initiated at Overweight by JP Morgan
Dow Jones · 02/03 12:37
Aktis Oncology Price Target Announced at $30.00/Share by JP Morgan
Dow Jones · 02/03 12:37
Leerink Partners Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $31
Benzinga · 02/03 12:29
JP Morgan Initiates Coverage On Aktis Oncology with Overweight Rating, Announces Price Target of $30
Benzinga · 02/03 12:27
AKTIS ONCOLOGY INC <AKTS.O>: LEERINK PARTNERS INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $31
Reuters · 02/03 11:54
Aktis Oncology initiated with an Outperform at Leerink
TipRanks · 02/03 11:30
Aktis Oncology initiated with a Buy at BofA
TipRanks · 02/03 11:25
Aktis Oncology: Differentiated Miniprotein Radiopharma Platform Underpins Buy Rating and Multi-Billion Dollar Sales Potential
TipRanks · 02/03 10:46
Aktis Oncology initiated with a Buy at TD Cowen
TipRanks · 02/03 10:40
AKTIS ONCOLOGY INC <AKTS.O>: TD COWEN INITIATES COVERAGE WITH BUY RATING
Reuters · 02/03 10:38
Analysts Offer Insights on Healthcare Companies: Revvity (RVTY) and Aktis Oncology, Inc. (AKTS)
TipRanks · 02/03 10:10
Aktis Oncology initiated with an Overweight at JPMorgan
TipRanks · 02/03 10:00
More
Webull provides a variety of real-time AKTS stock news. You can receive the latest news about AKTIS ONCOLOGY INC through multiple platforms. This information may help you make smarter investment decisions.
About AKTS
Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.